• Leevi A Toivonen, Heikki Mäntymäki, Arja Häkkinen, Hannu Kautiainen, and Marko H Neva.
• Department of Orthopaedics and Trauma, University of Tampere, Faculty of Medicine and Life Sciences and Tampere University Hospital, Tampere, Finland.
• Spine. 2022 Feb 15; 47 (4): 303308303-308.

Study DesignProspective, follow-up study.ObjectiveWe aim to compare the rate of revisions for ASD after LSF surgery between patients with IS and DLSD.Summary Of Background DataASD is a major reason for late reoperations after LSF surgery. Several risk factors are linked to the progression of ASD, but the understanding of the underlying mechanisms is imperfect. If IS infrequently becomes complicated with ASD, it would emphasize the role of the ongoing degenerative process in spine in the development of ASD.Methods365 consecutive patients that underwent elective LSF surgery were followed up for an average of 9.7 years. Surgical indications were classified into 1) IS (n = 64), 2) DLSD (spinal stenosis with or without spondylolisthesis) (n = 222), and 3) other reasons (deformities, postoperative conditions after decompression surgery, posttraumatic conditions) (n = 79). All spinal reoperations were collected from hospital records. Rates of revisions for ASD were determined using Kaplan-Meier methods.ResultsAltogether, 65 (17.8%) patients were reoperated for ASD. The incidences of revisions for ASD in subgroups were 1) 4.8% (95% CI: 1.6%-22.1%); 2) 20.5% (95% CI: 15.6%-26.7%); 3) 20.6% (95% CI: 12.9%-31.9%). After adjusting the groups by age, sex, fusion length, and the level of the caudal end of fusion, when comparing with IS group, the other groups had significantly higher hazard ratios (HR) for the revision for ASD [2) HR (95% CI) 3.92 (1.10-13.96), P = 0.035], [3) HR (95% CI) of 4.27 (1.11-15.54), P = 0.036].ConclusionAmong patients with IS, the incidence of revisions for ASD was less than a 4th of that with DLSD. Efforts to prevent the acceleration of the degenerative process at the adjacent level of fusion are most important with DLSD.Level of Evidence: 3.Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

12 keywords...

hide…